The Hematologic Oncology Center cares for patients with hematologic and lymphatic system malignancies, including acute and chronic leukemias, Hodgkin and non-Hodgkin lymphomas, multiple myeloma, myelodysplastic syndromes and myeloproliferative disorders.
Among the physicians who are members of the center are hematologist/oncologists, who specialize in cancers of the blood and organs, stem cells, lymphatics, administration of chemotherapy, as well as other blood processes. Center physicians provide expert evaluation, diagnosis, staging and treatment for common and rare forms of these cancers and pre-cancerous disorders. Recognized leaders in their fields, members of the center have earned regional, national and international distinctions.
Adult Bone Marrow and Stem Cell Transplant Program at the Hematologic Oncology Center
The dedicated Adult Bone Marrow and Stem Cell Transplant Program is the largest on Long Island and Queens, performing both autologous and allogeneic transplants. This is the only transplant program in Long Island, Queens and Brooklyn that is accredited by the Foundation for Accreditation in Cellular Therapy (FACT). Accreditation is awarded because of exceptional patient care.
The program, which has been collecting bone marrow for unrelated donors for over 20 years, has recently been designated a National Marrow Donor Program (NMDP) Apheresis Collection Center.
Patients have access to the most current treatment approaches available through institutional review board (IRB) approved internally initiated clinical trials, as well as through affiliations with collaborative organizations:
- Many phase I and II drug trials utilizing the latest novel approaches to treatment are conceived and developed by the center’s physicians who maintain close working relationships with the major pharmaceutical research and development companies.
- The center is a National Cancer Institute (NCI)-designated Community Clinical Oncology Program and a main member institution in the cutting-edge NCI-sponsored cooperative group, the Alliance for Clinical Trials in Oncology (ACTION).
- The center is an active participant in many national clinical research cooperative groups, including the National Marrow Donor Program (NMDP), Blood and Marrow Transplantation Clinical Trials Network (BMT CTN), Center for International Blood and Marrow Transplant Research (CIBMTR),
Leukemia: Treatment and Research at the Hematologic Oncology Center
The Hematologic Oncology Center is one of the top referral centers in the nation for acute and chronic leukemia. The Chronic Lymphocytic Leukemia (CLL) Research and Treatment Program has become a landmark for CLL patients worldwide, offering comprehensive clinical care as well as providing extensive clinical and basic research of leukemia.
Over the years, the physicians have made a significant impact in the area of leukemia research:
- Center investigators have been involved in the earliest testing of novel agents for the therapy of acute leukemia, including inhibitors of drug resistance, immunotherapies and new chemotherapeutic agents
- In collaboration with Cold Spring Harbor and Ohio State University, the center’s oncologists have helped to identify subtypes of acute leukemia and developed prognostic models for the treatment of acute leukemia
- The center has also been instrumental in bringing in promising new drugs like GS-1101 (formerly CAL-101) and PCI-32765 (ibrutinib) for the treatment of advanced CLL and mantle cell lymphoma
The center’s leukemia patients receive the finest inpatient care at North Shore University Hospital, which has the only dedicated 30-bed leukemia unit in Long Island, Queens and Brooklyn. The unit has been providing exceptional care for leukemia patients since 1992.
Myelodysplastic Syndrome (MDS): Treatment and Research at the Hematologic Oncology Center
The center believes that every research breakthrough has a direct effect on the quality of care available to patients. Center physicians are actively engaged in clinical trials for patients with MDS, including new drug studies targeting anemia, and have earned the distinction as a designated Myelodysplastic Syndromes Center of Excellence by the Myelodysplastic Syndromes Foundation. In addition, they are funded by the St. Baldrick's Foundation to conduct research on MDS in young adults and children.